Influenza Treatment Market Updates : is Anticipated to Hit USD 1.22 Billion by 2026, Owing to Rise in Incidences of Influenza Across the Globe

Allied Market Research recently published a report, titled, "Influenza Treatment Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Global Opportunity Analysis and Industry Forecast, 2019-2026".

According to the report, the global influenza treatment industry was pegged at $861.5 million in 2018, and is projected to hit $1.22 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 https://www.alliedmarketresearch.com/request-sample/A06106

In 2018, the oseltamivir phosphate segment dominated the global influenza treatment market, comprising over two-fifths of the market share. Oseltamivir, endorsed by both the CDC and the American Academy of Pediatrics (AAP), is recommended for early flu treatment across all age groups, driving segment growth. However, the baloxavir marboxil segment is anticipated to exhibit the highest compound annual growth rate (CAGR) of 4.6% throughout the forecast period. Baloxavir marboxil is effective against influenza A strains resistant to oseltamivir, making it a preferred treatment option and bolstering segment growth.

Regarding distribution channels, the retail pharmacy segment is poised to register the highest CAGR of 4.7% during the forecast period, having also claimed the largest share in 2018, at nearly half of the global influenza treatment market. This dominance is attributed to the widespread presence of retail pharmacies worldwide and the convenience they offer. The analysis also covers segments such as hospital pharmacy and others.

North America dominated the market in 2018, contributing to approximately one-third of the total market share, driven by a surge in influenza infections. Conversely, the Asia-Pacific region is forecasted to witness the fastest CAGR of 5.6% during the forecast period, propelled by increased awareness regarding early diagnosis for more effective treatment.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭- https://www.alliedmarketresearch.com/connect-to-analyst/A06106

𝐌𝐚𝐣𝐨𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐩𝐥𝐚𝐲𝐞𝐫𝐬
AstraZeneca Plc
BioCryst Pharmaceuticals, Inc.
Daiichi Sankyo Company Limited
F. Hoffmann-La Roche AG
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Teva Pharmaceutical Industries Limited

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
• Oseltamivir phosphate occupied more than two-fifth share of the global influenza treatment market in 2018.
• The others segment in distribution channel pharmacy segment is anticipated to grow with the highest CAGR throughout the forecast period.
• The others segment in product type accounted for more than two-fifth share of the market in 2018.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

𝑲𝑬𝒀 𝑩𝑬𝑵𝑬𝑭𝑰𝑻𝑺 𝑭𝑶𝑹 𝑺𝑻𝑨𝑲𝑬𝑯𝑶𝑳𝑫𝑬𝑹𝑺
This report entails a detailed quantitative analysis along with the global influenza treatment market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The influenza treatment market forecast is studied from 2018 to 2026.
The market size and estimations are based on a comprehensive analysis of key developments in the influenza treatment industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the influenza treatment market.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/influenza-treatment-market-A06106

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Follow Us on Blog: https://www.dailyreportsworld.com/

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view of providing business insights and consulting to assist its clients in making strategic business decisions and achieving sustainable growth in their respective market domain.

We have professional corporate relations with various companies and this helps us dig out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high-quality of data and help clients in every way possible to achieve success. Each and every piece of data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.